Abstract
Lung cancer is a highly prevalent disease worldwide. Currently, there are more than 150 million patients with lung cancer in the world, with more than 1 million new cases diagnosed per year. Tumoral angiogenesis is an important hallmark of this disease, but despite being extensively studied, the complete angiogenic mechanisms are not fully elucidated. Recent studies have reported a correlation between pharmacological inhibition of these angiogenic mechanisms and improvement of overall survival in lung cancer patients, mainly for those in advanced stages. The family of vascular endothelial growth factor (VEGF) proteins has critical roles in tumoral angiogenesis. An interaction between VEGF-A and VEGF receptor 2 (VEGFR-2) is the main pathway of activation and maintenance of angiogenesis. In tumors, this process is intimately correlative with progression and metastasis. Some studies suggested that serum levels of VEGF are higher in patients with lung cancer, especially in some types of non-small cell lung cancer (NSCLC). Other studies revealed that genetic polymorphisms of VEGF correlate with susceptibility, prognosis, and therapeutic response of some patients with NSCLC. This paper aims to review the impact of angiogenesis, especially on VEGF pathways, in NSCLC, and highlights the relevance of known and new patents disclosed of anti-angiogenic therapies in these patients.
Keywords: Angiogenesis, antineoplastic drug combination, biological markers, neovascularization, non-small cell lung cancer, pathology, polymorphism, vascular endothelial growth factor, Tumor Vessel Creation, VEGF pathway
Recent Patents on Anti-Cancer Drug Discovery
Title: Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
Volume: 7 Issue: 1
Author(s): Ramon Andrade de Mello, Bruno M. Costa, Rui M. Reis and Venceslau Hespanhol
Affiliation:
Keywords: Angiogenesis, antineoplastic drug combination, biological markers, neovascularization, non-small cell lung cancer, pathology, polymorphism, vascular endothelial growth factor, Tumor Vessel Creation, VEGF pathway
Abstract: Lung cancer is a highly prevalent disease worldwide. Currently, there are more than 150 million patients with lung cancer in the world, with more than 1 million new cases diagnosed per year. Tumoral angiogenesis is an important hallmark of this disease, but despite being extensively studied, the complete angiogenic mechanisms are not fully elucidated. Recent studies have reported a correlation between pharmacological inhibition of these angiogenic mechanisms and improvement of overall survival in lung cancer patients, mainly for those in advanced stages. The family of vascular endothelial growth factor (VEGF) proteins has critical roles in tumoral angiogenesis. An interaction between VEGF-A and VEGF receptor 2 (VEGFR-2) is the main pathway of activation and maintenance of angiogenesis. In tumors, this process is intimately correlative with progression and metastasis. Some studies suggested that serum levels of VEGF are higher in patients with lung cancer, especially in some types of non-small cell lung cancer (NSCLC). Other studies revealed that genetic polymorphisms of VEGF correlate with susceptibility, prognosis, and therapeutic response of some patients with NSCLC. This paper aims to review the impact of angiogenesis, especially on VEGF pathways, in NSCLC, and highlights the relevance of known and new patents disclosed of anti-angiogenic therapies in these patients.
Export Options
About this article
Cite this article as:
Andrade de Mello Ramon, M. Costa Bruno, M. Reis Rui and Hespanhol Venceslau, Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies, Recent Patents on Anti-Cancer Drug Discovery 2012; 7 (1) . https://dx.doi.org/10.2174/157489212798357994
DOI https://dx.doi.org/10.2174/157489212798357994 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer
Current Cancer Drug Targets Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry CBP-dependent Wnt/β-catenin signaling is crucial in regulation of MDR1 transcription
Current Cancer Drug Targets Thymoquinone Anticancer Discovery: Possible Mechanisms
Current Drug Discovery Technologies Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy The Role of B Cell Receptor Stimulation in CLL Pathogenesis
Current Pharmaceutical Design Nanomaterials for Targeted Delivery of Anticancer Drugs: An Overview
Current Nanomaterials Synthesis, Anticancer, and Antibacterial Studies of Benzylidene Bearing 5-substituted and 3,5-disubstituted-2,4-Thiazolidinedione Derivatives
Medicinal Chemistry Role of Active Drug Transporters in Refractory Multiple Myeloma
Current Topics in Medicinal Chemistry Cytotoxic Molecules from Natural Sources: Tapping the Brazilian Biodiversity
Anti-Cancer Agents in Medicinal Chemistry Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting
Current Gene Therapy Pentacyclic Triterpenoids and Their Saponins with Apoptosis-Inducing Activity
Current Topics in Medicinal Chemistry Expression of P-gp, MRP, LRP, GST-π and TopoIIα and Acquired Resistance to Cisplatin in Human Lung Adenocarcinoma Cells
Letters in Drug Design & Discovery Chemical Inhibition of Matrix Metalloproteinases for Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Polynucleotide Kinase as a Potential Target for Enhancing Cytotoxicity by Ionizing Radiation and Topoisomerase I Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Metal Oxide Nanomaterials in Nanomedicine: Applications in Photodynamic Therapy and Potential Toxicity
Current Topics in Medicinal Chemistry Improving Safety of Gene Therapy
Current Drug Safety Changes in Glutathione, Oxidative Stress and Mitochondrial Membrane Potential in Apoptosis Involving the Anticancer Activity of Cantharidin Isolated from Redheaded Blister Beetles, Epicauta hirticornis
Anti-Cancer Agents in Medicinal Chemistry Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling
Current Medicinal Chemistry